Dabrafenib mesylate detailed instructions

Drug name: Dabrafenib mesylate

Common name: Dabrafenib Mesylate

Drug classification: Targeted therapy drugs

1.Indications:

Dabrafenib mesylate is mainly used to treat advanced or metastatic malignant melanoma (melanoma) carrying BRAF V600 mutations. In addition, dabrafenib mesylate may be used as monotherapy in a subset of patients with inoperable or metastatic NSCLC whose tumors harbor the BRAF V600E mutation. In the United States, dabrafenib mesylate is also approved for the treatment of benign meningiomas associated with the BRAF V600E mutation.

2.Ingredients:

The active ingredient of dabrafenib mesylate is Dabrafenib Mesylate. Each tablet dose contains a specific dose of the active ingredient, usually measured in units of 50 milligrams or 75 milligrams.

3.Pharmacological effects:

Dabrafenib mesylate is a BRAF kinase inhibitor. It blocks the phosphorylation activity of BRAF protein by binding to the activation site of BRAF protein, thereby inhibiting the activation of downstream signaling pathways. This effect can effectively inhibit the growth and spread of cancer cells carrying the BRAF V600 mutation.

4.Dosage form and dosage:

Dabrafenib mesylate is available in tablet form, with a common dose of 150 mg once daily taken orally twice daily. Dosage selection is usually determined by the physician based on the patient's specific condition and severity of illness, and may require individualized adjustments.

5.Route of administration:

Dabrafenib mesylate is administered orally and is recommended to be taken on an empty stomach. Take the required dose on time every day as recommended and prescribed by your doctor.

6.Adverse reactions:

Common adverse reactions of dabrafenib mesylate include skin reactions (such as rash, dryness, itching), fever, headache, nausea, fatigue, etc. Serious adverse reactions may include bleeding, heart problems, abnormal liver function, etc. Patients should pay attention to observe adverse reactions during medication and report them to the doctor in a timely manner.

Precautions and contraindications:

Dabrafenib mesylate may interact with other drugs. Tell your doctor about all the drugs you are taking, including prescription drugs, over-the-counter drugs, and supplements.

Pregnant and breastfeeding women should avoid the use of dabrafenib mesylate.

Patients should be monitored and followed up regularly during treatment with dabrafenib mesylate to ensure treatment efficacy and safety.

Dabrafenib mesylate is contraindicated in patients with serious heart problems or a tendency to bleed.

7.Storage conditions:

Dabrafenib mesylate should be stored at room temperature (15-30C) away from light and moisture to ensure the stability and effectiveness of the drug.

Dabrafenib is now on the market in China and has been included in medical insurance. Patients can purchase it domestically. However, its price is relatively high, about 10,000 yuan. Please consult the local hospital pharmacy for specific prices. In comparison, the price of foreign generic drugs of dabrafenib is more affordable, especially the price of generic drugs in Laos, which is only about two to three thousand yuan, which is far lower than the domestic price. It should be noted that these foreign generic drugs are highly similar in drug ingredients to domestic original drugs. Therefore, patients can flexibly choose a suitable drug source based on their own economic situation and actual needs.

Dabrafenib mesylate is an effective targeted therapy used to treat certain types of cancer. Its primary role is to inhibit the growth and spread of cancer cells carrying the BRAF V600 mutation. Patients should read the drug instructions carefully before using dabrafenib mesylate and follow the doctor's recommendations and prescriptions to ensure the best therapeutic effect and safety.

xa0